# EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

> **NCT07262619** · PHASE1,PHASE2 · RECRUITING · sponsor: **Eikon Therapeutics** · enrollment: 160 (estimated)

## Conditions studied

- Advanced Solid Tumors
- MSI-H or dMMR Advanced Solid Tumors
- MSI-H/dMMR Gastric Cancer
- MSI-H/dMMR Colorectal Cancer
- MSI-H/dMMR Gastroesophageal-junction Cancer
- Endometrial Cancer
- Mismatch Repair Deficient or MSI-High Solid Tumors

## Interventions

- **DRUG:** EIK1005
- **DRUG:** pembrolizumab (KEYTRUDA® )

## Key facts

- **NCT ID:** NCT07262619
- **Lead sponsor:** Eikon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07262619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07262619, "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07262619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*